Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.9%

7 terminated/withdrawn out of 773 trials

Success Rate

95.3%

+8.8% vs industry average

Late-Stage Pipeline

11%

88 trials in Phase 3/4

Results Transparency

4%

6 of 141 completed trials have results

Key Signals

165 recruiting6 with results

Enrollment Performance

Analytics

N/A
260(53.2%)
Phase 2
97(19.8%)
Phase 4
53(10.8%)
Phase 3
35(7.2%)
Phase 1
29(5.9%)
Early Phase 1
15(3.1%)
489Total
N/A(260)
Phase 2(97)
Phase 4(53)
Phase 3(35)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (773)

Showing 20 of 773 trials
NCT07620626Recruiting

Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment

Role: collaborator

NCT07632235Phase 1Not Yet Recruiting

A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

Role: collaborator

NCT07632365Phase 1Active Not Recruiting

Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer

Role: collaborator

NCT07527936Early Phase 1Suspended

A Study of BEN301 Injection in theTreatment of Autoimmune Diseases

Role: lead

NCT05941377Not ApplicableCompleted

China Antihypertensive Trial for Intracranial Aneurysm

Role: collaborator

NCT07622212Recruiting

Comparison Of Different Mechanical Thrombectomy Devices in Endovascular Treatment of Acute Iliofemoral Venous Thrombosis

Role: lead

NCT07622199Not ApplicableNot Yet Recruiting

PROfunda Femoris Vein Thrombosis Evaluation and Clearance to Improve Outcomes of Endovascular Treatment for Acute Iliofemoral Deep Vein Thrombosis

Role: lead

NCT07614191Early Phase 1Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of GT801 Injection in the Treatment of Moderate to Severe Refractory Autoimmune Diseases

Role: collaborator

NCT05858684Early Phase 1Recruiting

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

Role: lead

NCT06851663Phase 2Recruiting

Trop2-targeted immunoPET Imaging of Solid Tumors

Role: lead

NCT07608224Phase 2Not Yet Recruiting

HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBC

Role: collaborator

NCT07602101Phase 2Not Yet Recruiting

Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma

Role: lead

NCT06035224Phase 2Active Not Recruiting

Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma

Role: lead

NCT07591805Phase 2Not Yet Recruiting

HERO-UTUC: Intravesical RC48 After RNU for HER2+ UTUC

Role: lead

NCT07165470Not ApplicableRecruiting

Pre-Packaged Low-Residue Diet Assisting Bowel Preparation in Patients With Inflammatory Bowel Disease

Role: collaborator

NCT07353853Not ApplicableRecruiting

Pre-packaged Low-residue Diet for Bowel Preparation in Patients With Inflammatory Bowel Disease

Role: collaborator

NCT07335705Recruiting

Analysis of Factors Influencing the Quality of Bowel Preparation Before Colonoscopy in IBD Patients

Role: collaborator

NCT05831878Not ApplicableRecruiting

RC48-ADC in HER2-low Advanced Breast Cancer

Role: lead

NCT05831891Phase 2Active Not Recruiting

Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell Carcinoma

Role: lead

NCT07283692Phase 2Recruiting

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Role: lead